Anti-IL-6

Anti-interleukin-6 agents are a recent class of therapeutics.

Interleukin-6 is relevant to many inflammatory diseases and many cancers. Hence anti-IL-6 agents have been sought.

The first approved, tocilizumab (Actemra), actually acts against the IL-6 receptor.

In clinical trials : Elsilimomab for some cancers, Anti-IL-6 chimeric monoclonal antibody (CNTO 328), ALD518, CNTO 136, CPSI-2364, CDP6038.

Pre-clinical : VX30 for rheumatoid arthritis. Also ARGX-109, FE301 , FM101

Food/diet
It has been reported that lunasin, a soy peptide, reduces inflammation by reducing interleukin-6 and may help in leukemia.

Luteolin reduces IL-6 production in some neurons.